Drug intelligence / Profile preview

HAI chronomodulated chemotherapy

Development stage
Phase 3
Lead developer
Hôpital Paul Brousse
Modality
Small Molecules
Administration
Intra-arterial
01

Overview

HAI chronomodulated chemotherapy refers to the delivery of chemotherapeutic agents directly into the hepatic artery (hepatic arterial infusion, HAI) using a schedule that is synchronized with the patient’s circadian rhythms (chronotherapy). This approach aims to maximize antitumor efficacy against liver metastases—most commonly from colorectal cancer—while minimizing toxicity to healthy liver tissue. The regimen typically involves multidrug combinations such as 5-fluorouracil, oxaliplatin, and irinotecan administered via programmable pumps that deliver drugs in sinusoidal patterns aligned with biological clocks. Chronotherapy exploits differences in drug metabolism and cell cycle timing between tumor and normal cells; detoxification pathways in normal liver are regulated by circadian genes but are often disrupted in tumors. Clinical studies suggest this method can improve tolerability and response rates even in heavily pretreated patients[3][5][6]. The OPTILIV protocol is one example of a triplet-chemotherapy-based HAI regimen delivered with chronomodulation[5].

Other names
hepatic arterial infusion chronomodulated chemotherapyregional chronomodulated hepatic arterial infusion chemotherapyHAIC chronomodulation
02

Targets

TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on HAI chronomodulated chemotherapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HAI chronomodulated chemotherapy.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call